A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

NCT00704080 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Mixed Gliomas
Malignant Gliomas
Glioblastoma Multiforme

Interventions

DRUG: XL765 (SAR245409)
DRUG: Temozolomide

Sponsor

Sanofi